Gateway Investment Advisers LLC Sells 211 Shares of Alnylam Pharmaceuticals, Inc. (ALNY)

Gateway Investment Advisers LLC cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,320 shares of the biopharmaceutical company’s stock after selling 211 shares during the period. Gateway Investment Advisers LLC’s holdings in Alnylam Pharmaceuticals were worth $404,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. FUKOKU MUTUAL LIFE INSURANCE Co grew its position in Alnylam Pharmaceuticals by 40.0% during the fourth quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 700 shares of the biopharmaceutical company’s stock worth $51,000 after buying an additional 200 shares in the last quarter. Resources Investment Advisors Inc. acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $58,000. Huntington National Bank acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $73,000. ETF Managers Group LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 15.7% in the 4th quarter. ETF Managers Group LLC now owns 1,086 shares of the biopharmaceutical company’s stock worth $79,000 after acquiring an additional 147 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Alnylam Pharmaceuticals by 768.5% in the 3rd quarter. Tower Research Capital LLC TRC now owns 1,294 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 1,145 shares in the last quarter. Institutional investors and hedge funds own 87.13% of the company’s stock.

ALNY has been the topic of several recent analyst reports. Cowen reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 6th. Chardan Capital reissued a “buy” rating and issued a $150.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, April 9th. ValuEngine raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 1st. Needham & Company LLC reissued a “buy” rating and issued a $135.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, February 8th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $135.00 target price on shares of Alnylam Pharmaceuticals in a report on Thursday, February 7th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and fifteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $130.24.

In other Alnylam Pharmaceuticals news, Director Philip A. Sharp sold 15,000 shares of the company’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $88.23, for a total transaction of $1,323,450.00. Following the completion of the sale, the director now owns 250,633 shares in the company, valued at approximately $22,113,349.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 3.60% of the company’s stock.

ALNY stock traded down $0.68 during trading on Friday, hitting $71.46. The company had a trading volume of 1,419,227 shares, compared to its average volume of 1,302,074. The stock has a market capitalization of $7.69 billion, a PE ratio of -9.44 and a beta of 2.53. Alnylam Pharmaceuticals, Inc. has a 12 month low of $60.27 and a 12 month high of $124.21. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.33 and a quick ratio of 6.56.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.73) EPS for the quarter, beating the consensus estimate of ($2.20) by $0.47. The company had revenue of $33.29 million during the quarter, compared to analysts’ expectations of $21.60 million. Alnylam Pharmaceuticals had a negative net margin of 929.51% and a negative return on equity of 55.33%. The business’s revenue for the quarter was up 52.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.22) EPS. As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -8.64 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Gateway Investment Advisers LLC Sells 211 Shares of Alnylam Pharmaceuticals, Inc. (ALNY)” was reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.baseballdailydigest.com/news/2019/05/11/alnylam-pharmaceuticals-inc-alny-position-trimmed-by-gateway-investment-advisers-llc.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Featured Article: Price-Sales Ratio

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.